Market Overview

G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results

Share:
G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results

G1 Therapeutics Inc (NASDAQ: GTHX) reported positive top-line results Wednesday for its Phase 2 trilaciclib trial in small cell lung cancer.

What Happened

The candidate met primary endpoints in reducing the occurrence and duration of severe neutropenia. Compared to the placebo, it also allowed physicians to cut granulocyte-colony stimulating factor administrations by 45 percent and red blood cell transfusions by 58.7 percent, according to G1

At the same time, the placebo yielded superior results for objective response rate and clinical benefit rate, and it reported a comparable progression-free-survival rate.

“Remember that myelopreservation, not efficacy, was the primary endpoint,” H.C. Wainwright analyst Edward White said in a note.

Why It’s Important

The market reacted to the news with a sell-off, pressing the stock down 30 percent. Yet some experts rose to G1’s defense.

H.C. Wainwright projects 2026 revenues of $1.1 billion for trilaciclib and maintained a Buy rating on the stock with a $75 price target.

“The company's core competencies in drug development give us confidence in its early stage pipeline,” White said, noting the candidate’s potential in first-, second- and third-line SCLC, non-SCLC and metastatic breast cancer.

Raymond James initiated coverage with a Strong Buy rating and $66 price target.

“We think that the commercial argument for trilaciclib is currently underappreciated,” said analyst Dane Leone. The analyst forecast 2020 FDA approval for SCLC and triple-negative breast cancer, with 2023 sales striking $742 million. By 2027, they should bring in $2.2 billion, he said. 

What’s Next

G1 plans to meet with U.S. and European regulators in early 2019 to pursue the myelopreservation label. A regulatory update will follow in the second quarter, and G1 said it will strategize commercialization and market research throughout the year.

G1 shares were down 27.76 percent at $20.77 at the time of publication Thursday.

Related Links:

HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets

Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Latest Ratings for GTHX

DateFirmActionFromTo
Aug 2019UpgradesNeutralOverweight
Feb 2019Initiates Coverage OnBuy
Jan 2019DowngradesOverweightNeutral

View More Analyst Ratings for GTHX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Price Target Initiation Reiteration FDA Analyst Ratings Best of Benzinga

 

Related Articles (GTHX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
IINDoughertyAssumes34.0
PNRJefferiesInitiates Coverage On
YYUBSUpgrades
ROKUOppenheimerMaintains155.0
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

The Positives, Negatives Of Altria's $12.8-Billion Investment In Juul Labs

Experts Break Down Fed Commentary, Markets Disagree With Powell